Literature DB >> 8062131

Expression and nuclear translocation of the rel/NF-kappa B-related morphogen dorsal during the immune response of Drosophila.

J M Reichhart1, P Georgel, M Meister, B Lemaitre, C Kappler, J A Hoffmann.   

Abstract

The rel/NF-kappa B-related morphogen dorsal is a maternally expressed gene which is involved in the control of the dorso-ventral axis during early embryogenesis of Drosophila. We show that this gene is also expressed in the fat body of larvae and adults of Drosophila as well as in a tumorous blood cell line: its expression is noticeably enhanced upon bacterial (or lipopolysaccharide) challenge. This challenge also induces within 15-30 min a nuclear translocation of the dorsal protein. The genes encoding inducible antibacterial peptides in Drosophila contain kappa B-related nucleotide sequences and we show that the dorsal protein can bind to such motifs and sequence-specifically transactivate a reporter gene in co-transfection experiments with a Drosophila cell line. However, in dl1 mutants, in the absence of dorsal protein, the genes encoding antibacterial peptides retain their inducibility, suggesting a multifactorial control. The results indicate that in addition to its role in embryogenesis, dorsal is involved in the immune response of Drosophila. They also strengthen the analogy between the mammalian acute phase response and the insect immune response.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8062131

Source DB:  PubMed          Journal:  C R Acad Sci III        ISSN: 0764-4469


  25 in total

Review 1.  NF-kappaB in the immune response of Drosophila.

Authors:  Charles Hetru; Jules A Hoffmann
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10-07       Impact factor: 10.005

Review 2.  Worms and flies as genetically tractable animal models to study host-pathogen interactions.

Authors:  Eleftherios Mylonakis; Alejandro Aballay
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

3.  Adjacent GATA and kappa B-like motifs regulate the expression of a Drosophila immune gene.

Authors:  L Kadalayil; U M Petersen; Y Engström
Journal:  Nucleic Acids Res       Date:  1997-03-15       Impact factor: 16.971

4.  Immune factor Gambif1, a new rel family member from the human malaria vector, Anopheles gambiae.

Authors:  C Barillas-Mury; A Charlesworth; I Gross; A Richman; J A Hoffmann; F C Kafatos
Journal:  EMBO J       Date:  1996-09-02       Impact factor: 11.598

5.  A recessive mutation, immune deficiency (imd), defines two distinct control pathways in the Drosophila host defense.

Authors:  B Lemaitre; E Kromer-Metzger; L Michaut; E Nicolas; M Meister; P Georgel; J M Reichhart; J A Hoffmann
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

6.  Specificity of Rel-inhibitor interactions in Drosophila embryos.

Authors:  K Tatei; M Levine
Journal:  Mol Cell Biol       Date:  1995-07       Impact factor: 4.272

7.  A mosaic analysis in Drosophila fat body cells of the control of antimicrobial peptide genes by the Rel proteins Dorsal and DIF.

Authors:  P Manfruelli; J M Reichhart; R Steward; J A Hoffmann; B Lemaitre
Journal:  EMBO J       Date:  1999-06-15       Impact factor: 11.598

8.  A family of human receptors structurally related to Drosophila Toll.

Authors:  F L Rock; G Hardiman; J C Timans; R A Kastelein; J F Bazan
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-20       Impact factor: 11.205

9.  Origins of immunity: Relish, a compound Rel-like gene in the antibacterial defense of Drosophila.

Authors:  M S Dushay; B Asling; D Hultmark
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

10.  The Drosophila melanogaster toll pathway participates in resistance to infection by the gram-negative human pathogen Pseudomonas aeruginosa.

Authors:  Gee W Lau; Boyan C Goumnerov; Cynthia L Walendziewicz; Jennifer Hewitson; Wenzhong Xiao; Shalina Mahajan-Miklos; Ronald G Tompkins; Lizabeth A Perkins; Laurence G Rahme
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.